Recurrence  >>  pegylated liposomal doxorubicin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00030472: Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Terminated
2
US, Europe
pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
10/06
 
NCT01358071 / 2010-023613-61: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Completed
2
119
Europe
NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
AGC Biologics S.p.A.
Ovarian Cancer
12/16
12/16

Download Options